DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key axial spondyloarthritis  patient populations covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download.

Use the Extrapolated Worldwide Coverage dashboard to do the following:

  • View 10-year forecasts of the total prevalent cases of ankylosing spondylitis and total prevalent cases of axial spondyloarthritis for all 171 countries, stratified by region and World Bank income status.
  • Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
  • Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
  • Generate and export global heat maps of disease risk or patient population size.

The Extrapolated Worldwide Coverage dashboard is available as an Excel file in the “Downloads” section. It is available for purchase by clients who subscribe to all 45 countries covered by DRG Epidemiology. For subscription and entitlement queries, please contact questions@teamdrg.com.

Table of contents

  • Extrapolated Worldwide Coverage
    • Extrapolated Worldwide Coverage
      • Introduction
      • Download
      • The Global Extrapolator Model
      • The Global Extrapolation Algorithm
      • Bibliography

Author(s): Mudasir Khan, M.P.H; Abey John, MPH

Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.


Related Reports

Axial Spondyloarthritis | Unmet Need | Detailed, Expanded analysis: Ankylosing Spondylitis (US & EU)

In the last 15 years, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Ci...

View Details

Axial Spondyloarthritis | Landscape & Forecast | Disease Landscape & Forecast

The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (

View Details

Axial Spondyloarthritis | Current Treatment | Detailed, Expanded Analysis : Treatment Algorithms : Claims Data Analysis : Ankylosing Spondylitis (US)

MARKET OUTLOOK Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and th...

View Details

Axial Spondyloarthritis | Disease Landscape and Forecast | G7 | 2019

The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (

View Details